To compare the efficacy and safety of capecitabine and cyclophosphamide (XC) versus physician's choice as maintenance therapy for patients with advanced breast cancer who achieved disease control after salvage treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
86
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China
RECRUITINGProgression-Free Survival (PFS)
PFS is defined as the time from the date of starting maintenance therapy to the date of disease progression or death from any cause, whichever occurs first.
Time frame: From the date of starting maintenance therapy to the date of first documentation of disease progression or death from any cause (up to approximately 1 year)
Adverse events
Adverse events during maintenance therapy will be assessed according to the NCI CTCAE v5.0.
Time frame: From the date of starting maintenance therapy to the end of the treatment (up to approximately 1 year)]
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.